Shanghai Genechem Co., Ltd. (Genechem), a discovery company dedicated to novel 
drug target discovery and development of novel therapeutics, today announced 
the execution of a global collaboration with I-Mab (Nasdaq: IMAB), a 
Nasdaq-listed global biopharmaceutical company, to develop and commercialize 
multiple bi-specific antibodies (BsAb) based on monoclonal antibody developed 
by Genechem and antibodies selected by I-MAB.  

"This collaboration is the first of many that will leverage Genechem's Good 
Research Practice (GRP) and CHAMP antibody discovery platform, strong 
bioinformatic database, as well as strong development expertise of synergistic 
partners, to deliver globally competitive assets based on innovative targets. 
We are excited to collaborate with I-Mab, a global leader in Oncology and 
antibody development, to bring more products to address clinical unmet needs 
for patients in China and globally", commented Yueqiong Cao, Founder and CEO of 
Genechem.

About Shanghai Genechem Co., Ltd. (Genechem)

Genechem is a leading innovation research company focused on target 
discovery/validation, development of antibody and cell therapy products against 
novel targets, and partnership globally to maximize its portfolio. Founded in 
2002, now with over 500 employees, Genechem works closely with Research 
Oncologists to translate clinical research into therapeutics addressing high 
clinical unmet needs, leveraging its strong network of Research Oncologists in 
over 300 hospitals and Good Research Practice (GRP platform) which includes 
comprehensive RNAi library, tools including genetic typing, bioinformatic 
analysis, genetic manipulation, as well as SOP and project management systems. 
For more information, visit http://www.gcbio.com/.

Contact:
Dr. Tong Zhang
Chief Business Officer
Shanghai Genechem Co., Ltd
Tong.zhang@genechem.com.cn
+86-18501607878

Source: Shanghai Genechem Co., Ltd. (Genechem)